Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Saad Z. Usmani"'
Autor:
Sarah Norek, Reed Friend, Saad Z. Usmani, Manisha Bhutani, Lawrence J. Druhan, David M. Foureau, Katherine Rigby, James T. Symanowski, Barry Paul, Mallory Tucker, Myra M. Robinson, Mauricio Pineda-Roman, Shebli Atrash, Peter M. Voorhees
Publikováno v:
Blood. 138:2739-2739
Introduction: The treatment for RRMM in first relapse typically involves a triplet combination, with choice influenced by the type of treatment already received, and the initial response. Elotuzumab (Elo), an anti-SLAMF7 immunostimulatory monoclonal
Autor:
Barry Paul, Shebli Atrash, Lawrence J. Druhan, Fei Guo, Mauricio Pineda-Roman, David M. Foureau, Myra M. Robinson, Manisha Bhutani, Peter M. Voorhees, Saad Z. Usmani, James T. Symanowski, Reed Friend, Kateryna Fesenkova
Publikováno v:
Blood. 138:1585-1585
Introduction: The addition of elotuzumab (Elo), an anti SLAMF7 immunostimulatory antibody, to carfilzomib, lenalidomide and dexamethasone (KRd) can lead to synergistic anti-myeloma immune effects. Pre-clinical data showed that both Elo and KRd promot
Autor:
Shebli Atrash, Mauricio Pineda-Roman, Monika House, Carrie Ann Syfert, James T. Symanowski, Katherine K Farmer, Xhevahire Begic, Peter M. Voorhees, Saad Z. Usmani, Jiaxian He, Manisha Bhutani, Donna Acampora, Barry Paul, Sarah Norek, Reed Friend, David M. Foureau
Publikováno v:
Blood. 136:38-39
Background Studies combining Daratumumab with a proteasome inhibitor and/ or an immunomodulatory drug have shown to increase the duration and depth of response in patients with newly diagnosed multiple myeloma (NDMM). While assessment of minimal resi
Autor:
Honeylet Wortman-Vayn, Yizhou Fei, Anna Truppel-Hartmann, Suresh Shelat, Jesus G. Berdeja, Saad Z. Usmani, Steven Novick, Nina Shah
Publikováno v:
Blood. 136:18-19
BACKGROUND: Despite the introduction of novel agents, patients with high-risk (Revised International Staging System [R-ISS] stage III) newly diagnosed multiple myeloma (NDMM) have a poor prognosis (median progression-free survival [PFS], 29 months),
Autor:
Sagar Lonial, Hervé Avet-Loiseau, Michel Attal, Saad Z. Usmani, Robert Z. Orlowski, Hartmut Goldschmidt, Pieter Sonneveld, David S. Siegel, Jens Hillengass, Jesús F. San Miguel, Wee Joo Chng, Hermann Einsele, Maria-Victoria Mateos, Brian G.M. Durie, Jo Caers, Niels W.C.J. van de Donk, Joan Bladé, Antonio Palumbo, Robert A. Kyle, Kenneth C. Anderson, Philippe Moreau
Publikováno v:
Blood, 127(24), 2955-62. American Society of Hematology
Blood, 127(24), 2955-2962. American Society of Hematology
Sonneveld, P, Avet-Loiseau, H, Lonial, S, Usmani, S, Siegel, D, Anderson, K C, Chng, W-J, Moreau, P, Attal, M, Kyle, R A, Caers, J, Hillengass, J, San Miguel, J, van de Donk, N W C J, Einsele, H, Bladé, J, Durie, B G M, Goldschmidt, H, Mateos, M-V, Palumbo, A & Orlowski, R 2016, ' Treatment of multiple myeloma with high-risk cytogenetics : a consensus of the International Myeloma Working Group ', Blood, vol. 127, no. 24, pp. 2955-62 . https://doi.org/10.1182/blood-2016-01-631200
Blood, 127(24), 2955-2962. American Society of Hematology
Sonneveld, P, Avet-Loiseau, H, Lonial, S, Usmani, S, Siegel, D, Anderson, K C, Chng, W-J, Moreau, P, Attal, M, Kyle, R A, Caers, J, Hillengass, J, San Miguel, J, van de Donk, N W C J, Einsele, H, Bladé, J, Durie, B G M, Goldschmidt, H, Mateos, M-V, Palumbo, A & Orlowski, R 2016, ' Treatment of multiple myeloma with high-risk cytogenetics : a consensus of the International Myeloma Working Group ', Blood, vol. 127, no. 24, pp. 2955-62 . https://doi.org/10.1182/blood-2016-01-631200
The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were
Autor:
Hang Quach, Zandra Klippel, Meletios A. Dimopoulos, Xavier Leleu, Maria-Victoria Mateos, Saad Z. Usmani, Anita Zahlten-Kumeli, Katja Weisel, David S. Siegel, Ola Landgren, Hui Yang
Publikováno v:
Blood. 134:LBA-6
Introduction: The use of lenalidomide (LEN) and bortezomib (BTZ) in newly diagnosed multiple myeloma (MM) patients (pts), along with continuous or maintenance therapy paradigm have improved survival outcomes. However, many pts progress while on these
Autor:
Saad Z. Usmani, Lenka Capkova, Brittany Demers, Jiri Silar, Matyáš Kuhn, Jiri Minarik, Jeffrey A. Zonder, Evangelos Terpos, Andrew Spencer, Caitlin Costello, Dawn Marie Stull, Jan Straub, Ludek Pour, Jorge Vela-Ojeda, Jin Lu, Noemi Puig, Jennifer Elliott, Tomas Skacel, Michael A. Thompson, Frits van Rhee, Mario Boccadoro, Xavier Leleu, Vania Hungria, Robert M. Rifkin, Hans C. Lee, Kaili Ren, Kenny Galvez, Faith E. Davies, Ajai Chari, Alexandra Jungova, Rafat Abonour, Jesus G. Berdeja, Lucie Brožová, Roman Hájek, Magda Bařinová, Vladimir Maisnar, Gordon Cook, Katja Weisel
Publikováno v:
Blood. 134:1845-1845
Background Ixazomib, the first oral proteasome inhibitor, has been approved for >3 years in >70 countries, for the treatment of RRMM pts who have received ≥1 prior therapy, on the basis of the TOURMALINE-MM1 study, which reported an overall respons
Autor:
Mark A. Fiala, Saad Z. Usmani, Jatin J. Shah, Sundar Jagannath, Sagar Lonial, Shijie Tang, Saurabh Chhabra, Yubin Kang, Kelly N. Godby, Luciano J. Costa, Shaji Kumar, Arjun Lakshman, Robert F. Cornell, Paul G. Richardson, Noa Biran, Ehsan Malek, Ajai Chari, David S. Siegel, Michael Kauffman, Xiwen Ma, Amarendra K. Neppalli, Ujjawal H. Gandhi, Sharon Shacham, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari
Publikováno v:
Blood. 134:3125-3125
Introduction: Proteasome inhibitors (PI), immunomodulatory agents (IMiDs) and the CD38 monoclonal antibody daratumumab (dara) have transformed the management of MM, yet eventual refractoriness to these agents seems inevitable. Relapsed and refractory
Autor:
Shebli Atrash, Reed Friend, Peter M. Voorhees, Kelly Bumgarner, Daniel Auclair, Jeffrey A. Zonder, Myra M. Robinson, Barry Paul, Jordan Robinsons, Sarah Norek, Manisha Bhutani, Saad Z. Usmani, Ami Ndiaye, James T. Symanowski
Publikováno v:
Blood. 134:5570-5570
Background: Multiple myeloma (MM) remains an incurable malignancy; the majority of MM patients suffer relapses with progressively shorter disease-free intervals. Carfilzomib (CFZ) is a second-generation proteasome inhibitor (PI) with potent activity
Autor:
W. J. Chng, Michele Cavo, Shaji Kumar, Chang-Ki Min, Xavier Leleu, Charalampia Kyriakou, Sundar Jagannath, M.V. Mateos, Daniel D Waller, Je-Jung Lee, Ravi Vij, Evangelos Terpos, Chaim Shustik, Jens Hillengass, Heinz Ludwig, Dominik Dytfeld, Brian G.M. Durie, Parameswaran Hari, Hareth Nahi, Meral Beksac, Laura Rosiñol, Philippe Moreau, Ashraf Badros, Jin Seok Kim, Saad Z. Usmani, Ingela Turesson, Markus Hansson, Hyeon Seok Eom, H. Goldschmidt, Albert Oriol, E Kastritis, Tomer M Mark, Meletios A. Dimopoulos, Michel Delforge, J.J. Lahuerta, Elizabeth O'Donnell, J de la Rubia, Melissa Alsina, Paula Rodriguez Otero, Je-Hwan Lee, Ki-Hyun Kim, Ulf-Henrik Mellqvist, Henk M. Lokhorst, N W C J van de Donk, Shuji Ozaki, Enrique M. Ocio, Anna Sureda
Publikováno v:
LEUKEMIA
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Leukemia, 31(11), 2443-2448. Nature Publishing Group
Kumar, S K, Dimopoulos, M A, Kastritis, E, Terpos, E, Nahi, H, Goldschmidt, H, Hillengass, J, Leleu, X, Beksac, M, Alsina, M, Oriol, A, Cavo, M, Ocio, E M, Mateos, M V, O'Donnell, E K, Vij, R, Lokhorst, H M, Van De Donk, N W C J, Min, C, Mark, T, Turesson, I, Hansson, M, Ludwig, H, Jagannath, S, Delforge, M, Kyriakou, C, Hari, P, Mellqvist, U, Usmani, S Z, Dytfeld, D, Badros, A Z, Moreau, P, Kim, K, Otero, P R, Lee, J H, Shustik, C, Waller, D, Chng, W J, Ozaki, S, Lee, J J, De La Rubia, J, Eom, H S, Rosinol, L, Lahuerta, J J, Sureda, A, Kim, J S & Durie, B G M 2017, ' Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors : A multicenter IMWG study ', Leukemia, vol. 31, no. 11, pp. 2443-2448 . https://doi.org/10.1038/leu.2017.138
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Leukemia, 31(11), 2443-2448. Nature Publishing Group
Kumar, S K, Dimopoulos, M A, Kastritis, E, Terpos, E, Nahi, H, Goldschmidt, H, Hillengass, J, Leleu, X, Beksac, M, Alsina, M, Oriol, A, Cavo, M, Ocio, E M, Mateos, M V, O'Donnell, E K, Vij, R, Lokhorst, H M, Van De Donk, N W C J, Min, C, Mark, T, Turesson, I, Hansson, M, Ludwig, H, Jagannath, S, Delforge, M, Kyriakou, C, Hari, P, Mellqvist, U, Usmani, S Z, Dytfeld, D, Badros, A Z, Moreau, P, Kim, K, Otero, P R, Lee, J H, Shustik, C, Waller, D, Chng, W J, Ozaki, S, Lee, J J, De La Rubia, J, Eom, H S, Rosinol, L, Lahuerta, J J, Sureda, A, Kim, J S & Durie, B G M 2017, ' Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors : A multicenter IMWG study ', Leukemia, vol. 31, no. 11, pp. 2443-2448 . https://doi.org/10.1038/leu.2017.138
Background: Treatment of multiple myeloma has evolved considerably in the past few years with availability of several news drugs as well as increasing use of multidrug combinations. These changes have no doubt led to the improved survival seen among
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d6b476bc2bffe04a101a2f4419b785b
http://hdl.handle.net/11585/614587
http://hdl.handle.net/11585/614587